Parkinson's disease in China: a forty-year growing track of bedside work

Gen Li; Jianfang Ma; Shishuang Cui; Yixi He; Qin Xiao; Jun Liu; Shengdi Chen

doi:10.1186/s40035-019-0162-z

Parkinson's disease in China: a forty-year growing track of bedside work

Transl Neurodegener. 2019 Jul 31:8:22. doi: 10.1186/s40035-019-0162-z. eCollection 2019.

Authors

Gen Li^#¹, Jianfang Ma^#¹, Shishuang Cui¹, Yixi He¹, Qin Xiao¹, Jun Liu¹, Shengdi Chen^{1

2}

Affiliations

¹ 1Department of Neurology & Collaborative Innovation Center for Brain Science, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
² 2Co-innovation Center of Neuroregeneration, Nantong University, Jiangsu Province, China.

^# Contributed equally.

Abstract

The number and health burden of Parkinson's disease increase rapidly in China. It is estimated that China will have nearly half of the Parkinson's disease population in the world in 2030. In this review, we present an overview of epidemiology and health economics status of Parkinson's disease across China and discuss the risk factors of Parkinson's disease and related complications. From the view of clinical research, we also discuss the current status of clinical trials, diagnostic biomarkers, treatment of Parkinson's disease, tertiary network and post-occupation education in Chinese Parkinson's disease clinics.

Keywords: Clinical research; Diagnosis; Parkinson’s disease; Tertiary network.

Publication types

Review